Adherence to Asthma Biologics is a research paper published in CHEST Journal (2020). On theSindex it has a DataRank of 0.557. It has been cited 40 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.557
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NHLBI NIH HHS
Grant: R21 HL140287
National Institutes of Health
Grant: 3R21HL140287-02S1
Step down of asthma biologics in real-world practice settings
National Institutes of Health
FWCI
1.70
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study
Additional file 1 of Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study
Additional file 2 of Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study
Additional file 2 of Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study
Additional file 3 of Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study
Additional file 3 of Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study